Breaking News
March 24, 2019 - Hidden differences between pathology of CTE and Alzheimer’s disease discovered
March 24, 2019 - Knowing causative genes of osteoporosis may open door to more effective treatments
March 24, 2019 - Toilet-seat based cardiovascular monitoring system getting ready to begin commercialization
March 24, 2019 - New model for intensive care identifies factors that send ill patients to ICU
March 24, 2019 - Recommendations Issued for HSCT in Multiple Myeloma
March 24, 2019 - Deep brain stimulation provides sustained relief for severe depression
March 24, 2019 - “Statistical significance” may soon be a thing of past?
March 24, 2019 - Researchers track effects of epigenetic marks carried by sperm chromosomes
March 24, 2019 - AHA News: Family Adopts Three Children With Three Different Heart Conditions
March 24, 2019 - Research into opioid painkillers could provide clues for safer drug development
March 23, 2019 - Lung cancer survivor recounts her lifetime struggles
March 23, 2019 - Radial and femoral approach for PCI achieve similar results in terms of survival
March 23, 2019 - Study sheds light on the optimal timing of coronary angiography in NSTEMI patients
March 23, 2019 - Excess hormones could cause a condition that can lead to blindness in women, study finds
March 23, 2019 - Dramatic shifts in first-time opioid prescriptions bring hope, concern
March 23, 2019 - Antidepressant drugs may not work when neurons are out of shape
March 23, 2019 - TTUHSC El Paso to establish endowed chair in neurology through a major grant
March 23, 2019 - New device approved by FDA for treating patients with moderate-to-severe heart failure
March 23, 2019 - People with peripheral artery disease have lower Omega-3 Index, shows research
March 23, 2019 - Trigger warnings have minimal impact on how people respond to content, shows research
March 23, 2019 - Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
March 23, 2019 - Selfish genetic elements amplify inflammation and age-related diseases
March 23, 2019 - Study provides new understanding of how the brain recovers from damage caused by stroke
March 23, 2019 - CRISPR/Cas libraries could revolutionize drug discovery
March 23, 2019 - Allergic reaction during pregnancy may alter sexual-development in offspring’s brain
March 23, 2019 - Seeing through a robot’s eyes helps those with profound motor impairments
March 23, 2019 - Recent research shows that ease of breastfeeding after C-section differs culturally
March 23, 2019 - Newly discovered parameters offer more control over efficient release of drugs
March 23, 2019 - ‘De-tabooing’ of abortion- Women would like more support from health care community
March 23, 2019 - Anti-TB drugs can increase susceptibility to Mtb reinfection
March 23, 2019 - New survey indicates need of attention to neglected tropical diseases
March 23, 2019 - Innovative in vitro method to develop easy-to-swallow medicine for children and older people
March 23, 2019 - Sugary drinks could raise risk of early deaths finds study
March 23, 2019 - Lian wins ENGINE grant for stem-cell-based therapy to treat Type 1 diabetes
March 23, 2019 - Overall, Physicians Are Happy and Enjoy Their Lives
March 23, 2019 - Researchers discover how blood vessels protect the brain during inflammation
March 23, 2019 - CDC study shows modest improvement in optimal hospital breastfeeding policy
March 23, 2019 - Family-based prevention program to reduce alcohol use among older teens
March 23, 2019 - Remote monitoring of implanted defibrillators in heart failure patients prevents hospitalizations
March 23, 2019 - Appropriate doffing of personal protective equipment may reduce healthcare worker contamination
March 23, 2019 - Window screens can suppress mosquito populations, reduce malaria in Tanzania
March 23, 2019 - Researchers discover new biomarker for postoperative liver dysfunction
March 23, 2019 - Pregnancy history may be linked to cognitive function in older women, finds study
March 23, 2019 - Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack
March 23, 2019 - FDA Approves First Drug for Postpartum Depression, Zulresso (brexanolone)
March 23, 2019 - New guidelines outline new treatment management for psoriasis
March 23, 2019 - Thermally abused cooking oil may promote progression of breast cancer
March 23, 2019 - High-fructose corn syrup fuels growth of colon tumors in mice
March 23, 2019 - Partnership aims at establishing best practices to promote diversity in clinical trials
March 23, 2019 - New study examines presence of microbes in tap water from residences, office buildings
March 23, 2019 - Early life trauma may affect brain structure, contribute to major depressive disorder
March 23, 2019 - NIH starts clinical trial of drug to treat cravings associated with opioid use disorder
March 23, 2019 - Cervix bacteria, immune factors could be a warning signal of premature birth, reports new research
March 23, 2019 - Worst-ever emergency care performance figures underscore the need to focus on staffing
March 23, 2019 - The Current issue of “The view from here” is concerned with Cancer
March 23, 2019 - Mouse model validates how ‘good’ and ‘bad’ bacteria affect acne
March 23, 2019 - Individual amygdala neurons respond to touch, imagery and sounds
March 23, 2019 - Combination of two topical creams can prevent cancer
March 23, 2019 - Study suggests depression screening when assessing African-Americans for schizophrenia
March 23, 2019 - New electronic support system for choosing drug treatment based on patient’s genotype
March 23, 2019 - First-of-its-kind study provides pregnancy statistics of imprisoned U.S. women
March 23, 2019 - Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 23, 2019 - Laparoscopy: MedlinePlus Lab Test Information
March 23, 2019 - Shellfish allergies: can they be treated?
March 23, 2019 - Toilet seat heart monitoring system
March 23, 2019 - Researchers identify way to improve common treatment for PTSD
March 23, 2019 - High potency cannabis use linked to psychosis finds study
March 23, 2019 - Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
March 23, 2019 - Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
March 23, 2019 - Scientists grow most sophisticated brain organoid to date
March 23, 2019 - ADHD drug raising risk of psychosis
March 22, 2019 - FDA approves brexanolone, first drug developed to treat postpartum depression
March 22, 2019 - Gruesome cat and dog experiments by the USDA exposed
March 22, 2019 - Ball pits used in children’s physical therapy may contribute to germ transmission
March 22, 2019 - Long-term use of inexpensive weight-loss drug may be safe and effective
March 22, 2019 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 22, 2019 - Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
March 22, 2019 - Finding the right exercise, diet aids for HIV patients
March 22, 2019 - Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
March 22, 2019 - Researchers develop new tool for imaging large groups of neurons in living animals
Patients once thought incurable can benefit from high-dose radiation therapy

Patients once thought incurable can benefit from high-dose radiation therapy

image_pdfDownload PDFimage_print

In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The findings will be presented in a news briefing and the plenary session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) next week.

Generally, when a patient has a cancer that has spread to other parts of the body — called metastatic cancer — they are considered incurable. This multi-center trial challenged this idea by studying patients with a variety of oligometastatic cancers — that is, cancers that had been previously treated but then returned in a limited number of other parts of the body. The patients were treated with stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT), which is a form of high-precision cancer therapy that delivers substantially higher doses of radiation to the tumor site in just one or a few treatment sessions.

“Traditionally, when a patient had a cancer that spread to other parts of their body — such as to their bones or brain — they were considered to be incurable,” said David Palma, MD, PhD, lead author a researcher at Lawson Health Research Institute, the research institute of London Health Sciences Centre (LHSC) and lead institution of the multi-center study. “But there’s a theory — called the oligometastatic theory — that if a patient only has a few spots of cancer returning, those spots could be killed with radiation or surgery to improve their survival. Now, we’ve been able to show, for the first time in a randomized trial, that high-dose radiation can effectively treat these limited recurrences, and we’ve been able to increase survival by a median of 13 months.”

In this randomized, phase II, open-label study called SABR-COMET, Dr. Palma and his colleagues enrolled 99 patients from four countries (Canada, Scotland, the Netherlands and Australia). Each patient had been treated for cancer but the cancer had returned, with tumors appearing in as many as five different places. All patients had good performance status (ECOG 0-1) and a life expectancy of more than six months.

Patients had been diagnosed with a wide range of cancer types, most commonly breast (n=18), lung (n=18), colon or rectum (n=18) and prostate (n=16) cancers. In most patients (n=92), the cancer had spread to one to three new sites.

Between February 2012 and August 2016, the patients were randomized at a 1:2 ratio into two treatment arms: palliative standard of care treatments (SOC) and SOC plus stereotactic radiation therapy for all metastatic lesions. The median patient age was 68 years (range=43-89), and 59 percent of the patients were men. No baseline patient characteristics were significantly different between the two treatment arms. Median follow-up time was 27 months.

Patients who received SABR treatments lived considerably longer than those who did not. Median overall survival was 41 months (95 percent Confidence Interval: 26 months, upper limit not reached) for patients given stereotactic radiation, compared to 28 months (95% CI: 19, 33 months) in the standard treatment arm (stratified log rank p=0.09). This phase II trial was designed to look for a signal, defined as a p-value less than 0.20, as an initial comparison of these two treatment groups.

Stereotactic radiation also doubled the time patients lived without cancer growth. Progression-free survival was 12 months (95% CI: 6.9, 30 months) in the stereotactic radiation arm, compared to six months (95% CI: 3.4, 7.1 months) for those who received standard radiation therapy (p=0.001).

“We were surprised and quite pleased. We didn’t expect t survival benefit to be quite so long for patients with metastatic disease,” said Dr. Palma, also a clinician-scientist at the Ontario Institute for Cancer Research, which provided funding for this study.

Being treated with stereotactic radiation resulted in more negative side effects than standard treatments. Just 9 percent of patients who received standard treatments experienced serious adverse events (grade 2 or higher), while 30 percent of those in the SABR arm did (p=0.022). The most common negative side effects were fatigue (n=10), dyspnea, or difficulty breathing (n=9), muscle and joint pain (n=7), bone pain (n=6) or pain not otherwise specified (n=7). Three patients in the experimental arm died due to adverse events — one from a pulmonary abscess and one from subdural hemorrhage after surgery to repair a SABR-related perforated gastric ulcer and one from radiation pneumonitis. While such events can occur with standard radiation therapy, they are rare.

“Stereotactic radiation therapy needs to be delivered carefully and by an experienced team, and there is a small risk of very serious side effects, as well as mortality. But overall, for patients whose cancers have spread, and who are not expected to survive otherwise, the overall survival benefit of SABR appear to outweigh these risks,” said Dr. Palma.

There were no differences between the two treatment arms in quality of life measures, however. Scores on the Functional Assessment of Cancer Therapy: General (FACT-G) questionnaire at six months following treatment were similarly high for both patient groups (82.5 for SABR vs. 82.6 for standard therapy, p=0.992). Patients also reported similar quality of life outcomes on the physical, social, functional and emotional FACT-G subscales (all p>0.4).

In some cases, patients developed additional lesions during the trial. When this happened, noted Dr. Palma, the additional tumors could sometimes be successfully ablated. Because they were able to successfully treat a greater number of sites in these patients, the research team is now planning a follow-up study that will enroll patients with up to 10 metastatic lesions, called SABR-COMET-10.

“We don’t know the upward limit of how many tumors can be treated with SABR,” he said. “The concern is the amount of radiation exposure a patient can tolerate. We don’t know yet what the safe boundaries are. We’ve been very conservative, as this is a new technology.”

Nearly half (46 percent) of the patients treated with stereotactic radiation were still alive after five years, compared to 24 percent in the control group, said Dr. Palma — a result that he believes will encourage physicians to consider SABR as a treatment option.

“Ultimately, the question of whether an oncologist will offer this treatment as the standard of care for oligometastatic patients will be up to that oncologist,” he said. “At the very least, physicians should be considering this as a treatment option for their patients.”

“Stereotactic radiation therapy can increase how long these patients live and how long they live without their cancer coming back, and it doesn’t seem to have a detrimental impact on their quality of life.”

Source:

https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2018/High-dose-radiation-therapy-substantially-improves

Tagged with:

About author

Related Articles